An observational study in Idiopathic Granulomatous Mastitis, sponsored by Samsun Education and Research Hospital. Completed at 1 site in Turkey. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-08.
Sponsored by Samsun Education and Research Hospital · Observational
Albumin-to-globulin ratio (AGR) is an inflammation-based index that has been shown to have a role in many cancers and inflammatory diseases. Idiopathic granulomatous mastitis (IGM) is a rare inflammatory disease of the breast with a high recurrence rate. As a relatively new biomarker for inflammatory diseases, AGR's role in IGM recurrence has never been investigated in the literature. This study primarily investigates the possible risk factors for IGM recurrence and whether AGR can be used as a predictive factor.
Patients diagnosed with IGM on pathology reports between January 2016 and March 2021 were enrolled in the study and their medical records were analyzed retrospectively. The patients were divided into two groups: recurrence and non-recurrence. Clinical, demographic characteristics, and laboratory parameters were compared. The best cut-off value for significant factors in predicting recurrence was determined by receiver operating characteristic (ROC) analysis. Univariate and multivariate logistic regression analysis was used to determine the risk factors that are effective in IGM recurrence.
Patients diagnosed with IGM on pathology reports between January 2016 and March 2021
Exclusion Criteria:
Patients who recovered after IGM treatment and had no signs of relapse
Procedure: segmental mastectomy
Patients whose symptoms reappear 3 months after IGM treatment
Procedure: segmental mastectomy
The preferred method in the treatment of some patients diagnosed with IGM
Also known as: Incision and Drainage
IGM recurrence
Recurrence was defined as the reappearance of breast complaints such as pain, mass, abscess, and fistula at the end of at least three months following remission with treatment. IGM developed in the other breast after the treatment was also accepted as a recurrent case.
Time frame: within an average of 3-4 years of follow-up after treatment
Plan to share: Undecided — The datasets generated and analyzed in this study will be available from the corresponding author on reasonable request.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Samsun Education and Research Hospital